Sonrotoclax plus zanubrutinib for untreated CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CLL or SLL that is confirmed by a blood test or lymph node biopsy.
- You must be at least 65 years old.
- You must need treatment because of symptoms like anemia, low platelets, large lymph nodes, or weight loss.
- You must not have received prior treatment for CLL or SLL, except for certain steroids or rituximab for autoimmune problems.
- You must be willing to provide a bone marrow or blood sample before starting the trial to check for a unique marker that allows us to track the disease over time.
- You must be able to take oral medications and not have any serious bleeding disorders or recent heart problems.
- You must be in generally good health for your age (able to do daily activities) and have adequate kidney and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.